Select Language
Coagulation factor XI
Coagulation factor XI Overview
| English Name | Coagulation factor XI | Approved Drugs | 2 |
| Drugs in Clinical Trials | 30 | Target Synonym | EC 3.4.21，EC:3.4.21.27，FXI，F11，PTA，Coagulation Factor XI，Plasma Thromboplastin Antecedent，EC 3.4.21.27，Factor XI，Coagualtion Factor XI |
| Highest Development Stage | Approved | ||
| English Name | Coagulation factor XI |
| Target Synonym | EC 3.4.21，EC:3.4.21.27，FXI，F11，PTA，Coagulation Factor XI，Plasma Thromboplastin Antecedent，EC 3.4.21.27，Factor XI，Coagualtion Factor XI |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 30 |
| Highest Development Stage | Approved |
Coagulation factor XI Product List
- Product Category
Protein (2)
- Product Status
Launched (2)
- Species
Human (1)Rhesus macaque (1)
- Tag
His Tag (2)
- Conjugate
Unconjugated (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
FXI-H52H5 |  Human | HEK293 | Human Coagulation factor XI / FXI Protein, His Tag (active enzyme) |  |  |  |  Add to Cart |
FXI-C52H3 |  Rhesus macaque | HEK293 | Rhesus macaque Coagulation factor XI Protein, His Tag (Pro-form) |  | | | Add to Cart |
Total: 2
- 1
Coagulation factor XI Background
Coagulation factor XI is also known as F11, PTA and FXI. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Factor XI is synthesized in the liver and circulates in the plasma as a disulfide bond-linked dimer complexed with high molecular weight kininogen. Selective cleavage of Arg-|-Ala and Arg-|-Val bonds in factor IX to form factor IXa. Factor XI is converted into XIa via either the contact phase of blood coagulation or thrombin-mediated activation on the platelet surface. The resulting XIa converts factor IX into IXa, which subsequently activates factor X into Xa.
Coagulation factor XI Synonyms
Coagulation factor XI,FXI,PTA,F11
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Asundexian | BAY-2433334 | Phase 3 Clinical | Bayer AG | Atrial Fibrillation; Embolism; Hepatic Insufficiency; Ischemic Attack, Transient; Ischemic Stroke; Myocardial Infarction; Stroke; Thromboembolism | Details |
| Cenvacibart | REGN7508 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Atrial Fibrillation; Peripheral Arterial Disease; Thrombosis; Venous Thromboembolism | Details |
| Milvexian | BMS-986177; JNJ-70033093; JNJ-3093 | Phase 3 Clinical | Bristol-Myers Squibb Company | Acute Coronary Syndrome; Atrial Fibrillation; Contraception; Coronary Thrombosis; Embolism; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Renal Insufficiency; Stroke; Thromboembolism; Thrombosis | Details |
| SHR-2004 | SHR-2004 | Phase 3 Clinical | Beijing Suncadia Medicine Co Ltd | Arterial Thromboembolism; Atrial Fibrillation; Dyslipidemias; Thromboembolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis | Details |
| Amrecibart | REGN-9933 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Atrial Fibrillation; Peripheral Arterial Disease; Venous Thromboembolism | Details |
| Abelacimab | MAA-868; NOV-12 | Phase 3 Clinical | Novartis Pharma Ag | Atrial Fibrillation; Embolism; Neoplasms; Pulmonary Embolism; Stroke; Thromboembolism; Venous Thromboembolism; Venous Thrombosis | Details |
| EP-7041 | EP-7041; HSK-36273 | Phase 2 Clinical | Exithera Pharmaceuticals Inc | Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Thrombocytopenia; Thromboembolism; Thrombosis | Details |
| Osocimab | BAY-1213790 | Phase 2 Clinical | Bayer AG | Kidney Diseases; Kidney Failure, Chronic; Thromboembolism | Details |
| IONIS-FXIRX | ISIS-404071; BAY-2306001; ISIS-FXIRX; FXI-ASO; IONIS-FXIRX; ISIS-416858 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Thrombosis; Venous Thromboembolism | Details |
| MK-2060 | MK-2060 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Kidney Diseases; Kidney Failure, Chronic; Thromboembolism; Thrombosis | Details |
| SRSD-107 | SRSD-107; SRSD107 | Phase 2 Clinical | Sirius Therapeutics Inc | Arterial Thromboembolism; Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Peripheral Arterial Disease; Thromboembolism; Thrombosis; Venous Thromboembolism | Details |
| RBD-4059 | RBD-4059; RBD4059; SR059; SR-059 | Phase 2 Clinical | Suzhou Ribo Life Science Co Ltd | Coronary Artery Disease; Coronary Disease; Kidney Failure, Chronic; Venous Thrombosis | Details |
| KN-060 | KN-060; KN060 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Essential Hypertension; Hypertension; Kidney Failure, Chronic; Obesity; Overweight; Thromboembolism | Details |
| Ir-CPI | BIOX-101; Ir-CPI | Phase 2 Clinical | Free University Of Brussels | Cerebral Hemorrhage | Details |
| Fesomersen | ION-957943; IONIS-FXI-LRx; BAY-2976217 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Nephrosis; Thromboembolism | Details |
| ONO-7269 | ONO-7269 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Cerebral Infarction | Details |
| BAY-1831865 | AB-012; BAY-1831865 | Phase 1 Clinical | Aronora Inc | Thrombosis | Details |
| A-336 | A336; A-336 | Phase 1 Clinical | Klus Pharma | Thromboembolism | Details |
| A-186 | A-186 | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Thromboembolism | Details |
| BMS-262084 | BMS-262084 | Phase 1 Clinical | Bristol-Myers Squibb Company | Thrombosis | Details |
| ADX-626 | ADX-626 | Phase 1 Clinical | ADARx Pharmaceuticals Inc | Thrombosis | Details |
| SBK-013 | SBK013; SBK-013 | Phase 1 Clinical | Chengdu Shibeikang Biomedical Technology Co Ltd | Arterial Thromboembolism; Thromboembolism; Venous Thromboembolism | Details |
| XH-S002 | XH-S002; XHS002 | Phase 1 Clinical | Ischemic Attack, Transient; Stroke | Details | |
| BMS-986209 | BMS-986209 | Phase 1 Clinical | Bristol-Myers Squibb Company | Details | |
| NIP-003 | NIP003; NIP-003; CRB4101; CRB-4101 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Thromboembolism; Venous Thromboembolism; Venous Thrombosis | Details |
| Factor XIa Inhibitor (Bayer) | Factor XIa Inhibitor (Bayer) | Phase 1 Clinical | Bayer AG | Blood Coagulation Disorders | Details |
| SKB-336 | SKB-336 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Embolism; Thromboembolism | Details |
| SAL-0104 | SAL-0104; SAL0104 | Phase 1 Clinical | Suzhou Genemen Biotech Co Ltd | Cardiovascular Diseases; Embolism; Ischemic Attack, Transient; Myocardial Infarction; Stroke; Thrombosis; Venous Thromboembolism; Venous Thrombosis | Details |
| STP122G | STP-122G; STP122G | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Embolism and Thrombosis | Details |
| SHR2285 | SHR-2285 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Embolism; Thromboembolism; Thrombosis; Venous Thromboembolism | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Factor XI concentrate (factor XI deficiency), CSL Behring | Approved | Csl Behring Llc | Australia | Factor XI Deficiency | Csl Behring Llc | 2014-07-01 | Factor XI Deficiency | Details | ||
| Human coagulation Factor XI (LFB) | Approved | Lfb Biotechnologies Sas | Hemoleven | EU | Factor XI Deficiency | Lfb Biotechnologies Sas | 1999-07-01 | Factor XI Deficiency | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland